Using highly precise measurements, we found obstructive sleep apnea (OSA) was linked to poorer bone health at most sites. Higher oxygen saturation, rather than sleep efficiency, was beneficial. Total sleep duration was partially nonlinearly related to bone health. Patients with chronic sleep problems should be screened for low BMD. Previous studies have shown associations between sleep characteristics and bone health, but findings are inconsistent. This study investigated the relationships between objectively measured sleep characteristics and bone mineral density (BMD) as well as bone mineral content (BMC) using dual-energy X-ray absorptiometry (DXA) measurements at various skeletal sites. The analysis included data from 4690 participants aged 40–70 years in the Human Phenotype Project (HPP) cohort. Associations between total sleep time, mean oxygen saturation (
BACKGROUND:Amino acid metabolism plays a critical role in cardiovascular disease, yet its prognostic value in ST-elevation acute myocardial infarction (STEMI) remains underexplored. Therefore, we investigated whether specific plasma amino acid concentrations at admission for STEMI are associated with 28-day mortality. METHODS:This analysis was based on data from 724 patients with STEMI aged 29 to 98 years who were admitted to the University Hospital Augsburg between May 2009 and July 2013. Immediately after admission arterial blood samples were taken from these patients and a panel of amino acids was measured by a high-throughput nuclear magnetic resonance spectroscopy platform (Nightingale Health, Finland). Multivariable logistic regression models were conducted to examine the associations between the amino acids phenylalanine, tyrosine, glycine, alanine, histidine, glutamine, as well as branched-chain amino acids (BCAAs; a group that includes valine, isoleucine, and leucine) and 28-day mortality. P values were False discovery rate (FDR) adjusted. RESULTS:Altogether, 47 patients died within 28 days after admission. There were significant positive associations found between plasma levels of phenylalanine, glycine, tyrosine, valine, and alanine and 28-day mortality. Phenylalanine showed the highest effect estimate (OR: 1.84; 95% CI 1.34-2.53). No significant associations were observed for the remaining amino acids. CONCLUSIONS:The acute phase of STEMI is associated with changes in plasma amino acid levels that may reflect alterations in energy metabolism and metabolic stress. The associations between amino acid fluctuations and 28-day mortality highlight the potential of metabolomic profiling to refine early risk stratification.
Hip fractures in older adults are associated with substantial morbidity, functional decline, and mortality. Patients who experience a first fragility fracture are at high risk of subsequent fractures, with repeated events further exacerbating functional impairment and survival outcomes. Second contralateral hip fractures, while clinically important, remain under-characterized in terms of timing, long-term functional impact, and mortality. To investigate the incidence, timing, survival, mobility, and daily activity outcomes of second contralateral hip fractures using a matched pair analysis, and to situate these findings within the broader context of repeated fragility fractures. A retrospective cohort study was conducted at a single Level I trauma center, including all patients treated operatively for hip fractures (AO 31A1–A3, 31B) between January 2016 and June 2020. Patients with a second contralateral hip fracture were matched 1:1 with patients with a single fracture based on age, sex, fracture type, and Charlson Comorbidity Index. Demographic data, functional status (Barthel Index, Parker Mobility Score), walking aid use, living situation, and mortality were assessed at admission, discharge, and follow-up (minimum 3 years, maximum 7 years). Statistical analysis included paired tests and survival analysis. Of 1,933 patients, 148 (7.6
To evaluate the efficacy of somatostatin receptor (SSTR)-directed PET/CT in localizing phosphaturic mesenchymal tumors (PMT) in patients with suspected tumor-induced osteomalacia (TIO) and to explore relationships between imaging parameters and biochemical markers. This retrospective analysis included 20 patients with suspected TIO, undergoing SSTR-directed PET/CT. Imaging findings and laboratory markers were assessed. SSTR-positive tumors were resected, while patients without detectable tumor, but persistent renal phosphate wasting, continued on medical treatment. Follow-up assessments included laboratory values and clinical examinations. PMT were detected on PET in 12 patients (60
Tralokinumab is approved for the treatment of moderate-to-severe atopic dermatitis (AD) in patients aged ≥ 12 years. Here, we examined clinical laboratory parameters in adolescents with moderate-to-severe AD who were treated with tralokinumab for up to 1 year. This analysis assessed data from adolescents in the ECZTRA 6 (NCT03526861) phase 3 trial initiated on tralokinumab (150 mg or 300 mg) or placebo for 16 weeks. Additionally, pooled data from tralokinumab-treated patients who continued treatment beyond Week 16 were analyzed regardless of Week 16 response or tralokinumab dosing regimen (i.e., blinded 150 mg or 300 mg every 2 or 4 weeks or open-label tralokinumab 300 mg plus optional topical corticosteroids or calcineurin inhibitors). Median levels of most laboratory parameters were within respective reference ranges at baseline, Week 16, and Week 52, with comparable values across treatment groups at baseline and Week 16. Baseline levels for eosinophils and immunoglobulin E (IgE) were elevated across treatment groups. Few patients shifted from normal baseline eosinophil levels to moderate eosinophilia by Week 16 (150 mg, 3.4
